RLMD$3.91
$3.81
Chart
Performance
Key Stats
AI RLMD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralRelmada Therapeutics shows potential in its clinical pipeline but faces significant financial challenges and negative earnings. Current technical indicators are mixed, suggesting a wait-and-see approach is prudent. Further progress in clinical trials and positive cash flow generation are critical catalysts.
Thematic
Relmada operates in the promising biotechnology sector, focusing on novel treatments for neurological and oncological conditions. The company's development of treatments for Prader-Willi Syndrome, Tourette Syndrome, and bladder cancer aligns with growing healthcare needs, but the clinical stage nature of its products introduces substantial risk. Progress in clinical trials is the primary thematic driver.
Fundamental
Relmada Therapeutics demonstrates significant financial strain with consistent losses and no revenue. While its balance sheet shows some assets, the lack of profitability and negative cash flow from operations are major concerns. The current valuation metrics are distorted due to the absence of revenue.
Technical
Relmada Therapeutics (RLMD) is trading near its 52-week low, indicating a prolonged downtrend. While some short-term indicators show potential for minor bounces, the overall trend remains bearish. Key moving averages are signaling weakness, and recent price action suggests a lack of strong buying conviction.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 70 |
| Healthcare Sector Growth | 75 |
| Drug Development Risk | 40 |
| Competitive Landscape | 65 |
| Intellectual Property | 70 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 5 |
| Growth | 0 |
| Balance Sheet Health | 40 |
| Cash Flow | 10 |
| Earnings Per Share (EPS) | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 25 |
| Momentum | 50 |
| Moving Averages | 40 |
| Support & Resistance | 55 |
| Volume | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (4)
Improving Earnings Trend
While EPS has been negative (e.g., -0.58 in Q2 2025, -0.62 in Q1 2025), the reported EPS has been better than estimates in some recent quarters (e.g., Q1 2025 surprise of 11.24%, Q4 2024 surprise of 28.61%), indicating potential for positive surprises going forward. The next earnings date is May 12, 2025. [INDEX 11]
Mixed but Some Buy Signals
Some shorter-term moving averages like the Volume Weighted Moving Average (20) and Hull Moving Average (9) on the 1-minute and 5-minute charts suggest 'Buy' actions, indicating potential short-term interest. However, most longer-term moving averages and many oscillators across different timeframes suggest 'Sell' or 'Neutral' actions. [INDEX 16]
Bearish Points (6)
Consistent Negative Earnings
The company has consistently reported negative Earnings Per Share (EPS) on a trailing twelve months (TTM) basis (-$2.51), and all reported quarterly EPS figures are negative, indicating ongoing losses. [INDEX 4, INDEX 11]
No Revenue and Negative Earnings
The company has reported zero total revenue for the periods 2021-2024, and has negative net income in all analyzed periods. This results in undefined or highly negative Price-to-Earnings (P/E) and Price-to-Sales (P/S) ratios, making traditional valuation metrics uninformative and suggesting significant risk. [INDEX 25, INDEX 26, INDEX 23]
Calendar
September 2019
30
Next Dividend Date
August 2025
5
Next Earnings Date
H: $
A: $
L: $
Profile
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Seasonals
Price Target
1.00 USD
The 39 analysts offering 1 year price forecasts for RLMD have a max estimate of 1.00 and a min estimate of 1.00.
Financial Position Analysis
Ownership
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in Major Depressive Disorder (MDD) treatment with an approved NMDA receptor modulator (Auvelity), similar to Relmada's focus.
Weight: 95
Developer and marketer of Spravato (esketamine), an NMDA receptor modulator approved for treatment-resistant depression, a direct therapeutic class competitor.
Weight: 92
Focuses on CNS disorders, with an approved product (ZULRESSO) for postpartum depression and ZURZUVAE for PPD and MDD, making it a key competitor in depression.
Weight: 90
Develops and commercializes therapies for psychiatric and neurological disorders; its approved drug Caplyta is used for bipolar depression and schizophrenia, with ongoing MDD research.